HCA(US:HCA)2025-04-25 11:48Financial Performance - Revenues for Q1 2025 totaled $18.321 billion, a 5.7% increase from $17.339 billion in Q1 2024[2] - Net income attributable to HCA Healthcare, Inc. was $1.610 billion, or $6.45 per diluted share, compared to $1.591 billion, or $5.93 per diluted share in Q1 2024[2][17] - Adjusted EBITDA for Q1 2025 was $3.733 billion, up from $3.353 billion in Q1 2024[3] - Adjusted EBITDA for Q1 2025 was $3,733 million, representing a margin of 20.4%, compared to $3,353 million and a margin of 19.3% in Q1 2024[25] - The forecast for total revenues for the year ending December 31, 2025, is between $72,800 million and $75,800 million[30] - The projected net income attributable to HCA Healthcare, Inc. for 2025 is between $5,850 million and $6,290 million[30] Operational Metrics - Same facility admissions increased by 2.6% and same facility equivalent admissions rose by 2.8% compared to the prior year[4][5] - Admissions in Q1 2025 were 576,361, reflecting a 2.8% increase from 560,869 in Q1 2024[22] - The number of hospitals increased to 192 in Q1 2025 from 188 in Q1 2024, and licensed beds rose to 50,571 from 49,724[22] - The average length of stay in Q1 2025 was 4.922 days, slightly down from 4.959 days in Q1 2024[22] - The company reported a decrease in outpatient surgery cases by 2.5% in Q1 2025 compared to Q1 2024[22] Cash Flow and Debt - Cash flows from operating activities in Q1 2025 totaled $1.651 billion, down from $2.469 billion in Q1 2024[6] - As of March 31, 2025, total debt was $44.576 billion, with cash and cash equivalents of $1.060 billion[6] - Cash and cash equivalents at the end of Q1 2025 were $1,060 million, down from $1,933 million at the end of Q4 2024[20] Shareholder Returns - The company repurchased 7.762 million shares at a cost of $2.506 billion during Q1 2025[7] - A quarterly cash dividend of $0.72 per share was declared, payable on June 30, 2025[8] Guidance and Future Outlook - The company reaffirmed its 2025 estimated guidance ranges, expecting stable operating conditions and volume growth[10][11] - The Company does not forecast the impact of items such as losses on sales of facilities and legal claim costs due to the inability to predict these items accurately[33] Adjusted EBITDA - Adjusted EBITDA is not a measure of financial performance under GAAP but is considered important for discussions and analysis of operational results[33] - Management relies on Adjusted EBITDA as a primary measure to review and assess the operating performance of its health care facilities[33]